In-Vivo Imaging: Transforming Neuropsychology with Real-Time Brain Insights

Until relatively recently, understanding what happens inside a living, thinking brain required either waiting for post-mortem examination or relying on behavioral observations that could only hint at what was going on underneath. In-vivo imaging changed everything. By allowing scientists and clinicians to look directly inside the brain of a living person – without surgery, without harm – these techniques have fundamentally transformed how we study cognition, diagnose disease, and develop treatments. Today, tools like CT, MRI, PET, and fMRI sit at the heart of modern neuropsychology, giving us an unprecedented window into the organ that defines who we are.

What “in-vivo” actually means 🔗

The term in-vivo simply means “within the living.” In the context of brain science, it refers to examining the brain while a person is alive, as opposed to studying tissue extracted from a deceased patient. Neuroimaging – the broad category of techniques that produce images of the brain’s structure or activity – allows researchers and clinicians to observe the brain in action and identify abnormalities without any surgical intervention. This non-invasive quality is what makes these tools so powerful: they can be applied repeatedly, ethically, and safely across diverse populations, from healthy volunteers in research studies to critically ill patients in emergency settings.

In-vivo imaging methods generally fall into two categories. Structural imaging reveals the brain’s physical anatomy – its size, shape, and tissue composition. Functional imaging goes further by tracking activity in real time, showing which areas are working harder during specific tasks or under particular conditions. The four most widely used techniques in neuropsychology – CT, MRI, PET, and fMRI – each occupy a distinct role within this framework.

Computed tomography (CT): fast and clinically essential 🔗

Computed tomography works by passing a series of X-ray beams through the head from multiple angles. A computer then integrates these images to produce cross-sectional views of the brain’s internal structure. The result is a rapid, detailed snapshot of anatomy – but not of function.

CT’s greatest strength is speed. In emergency medicine, it remains the test of choice for quickly detecting acute brain events. It is particularly effective at identifying the four major types of intracranial hemorrhage – subdural, epidural, intracerebral, and subarachnoid – especially within the first 24 to 48 hours after injury. It is also used to detect skull fractures and significant brain swelling. Because CT scans can be completed quickly and are available in most hospitals, they are often the first imaging step taken when a patient arrives with a suspected brain injury or stroke.

The trade-off is that CT involves exposure to ionizing radiation and provides less soft-tissue contrast than MRI. It shows structure but cannot tell us how the brain is functioning, which is why it is often paired with other techniques for a fuller clinical picture.

Magnetic resonance imaging (MRI): the gold standard for brain structure 🔗

MRI has become the most commonly used brain-imaging method in both clinical practice and research. Rather than X-rays, MRI uses a powerful magnetic field – roughly 60,000 times stronger than Earth’s magnetic field – along with pulses of radio-frequency energy. This causes protons in the body’s hydrogen atoms to align and then emit detectable signals as they return to their resting state. Different types of tissue emit different signals, allowing the system to produce highly detailed images of gray matter, white matter, and other brain structures with millimeter-level resolution.

Structural MRI 🔗

Structural MRI (sMRI) creates 3D images of the brain’s anatomy. These images can reveal tumors, areas of inflammation or scarring, signs of degenerative diseases like multiple sclerosis, and the damage caused by stroke. Researchers also use structural MRI to compare brain volumes between groups – for example, examining whether certain regions associated with memory are smaller in individuals with depression, or whether motor areas are enlarged in professional musicians who have practiced for decades.

A specialized variant called Diffusion Tensor Imaging (DTI) focuses specifically on the brain’s white matter pathways – the myelinated axon bundles that transmit information between regions. DTI is highly sensitive to the movement of water molecules along these pathways, making it useful for detecting subtle damage to neural connectivity that might not appear on a standard MRI.

Why MRI is preferred for diagnostic imaging 🔗

Clinically, MRI is the preferred standard for characterizing whether there has been blood, a contusion, or significant axonal damage in the brain. It is also the primary tool for diagnosing stroke, tumor, and ischemic injury. Unlike CT, MRI involves no radiation, making it safer for repeated use over time – an important consideration when monitoring how a condition evolves or how a patient responds to treatment.

Functional MRI (fMRI): watching the brain think 🔗

Functional MRI uses the same scanner hardware as structural MRI but serves a fundamentally different purpose: instead of capturing a static picture of the brain’s anatomy, it measures brain activity as it changes over time. The key mechanism is the blood-oxygen-level-dependent (BOLD) signal. When a brain region becomes more active, it demands more oxygen, triggering an inflow of oxygenated blood. fMRI detects the resulting change in the concentration of oxygenated hemoglobin. Because cerebral blood flow is tightly coupled to neural activation, tracking the BOLD signal allows researchers to map which regions are engaged during specific tasks.

This has made fMRI an indispensable tool in cognitive neuroscience and neuropsychology. Researchers can observe which brain areas activate while a person reads, makes decisions, retrieves a memory, or processes emotional content – all in real time. Studies using fMRI have contributed enormously to our understanding of how the brain organizes language, attention, executive function, and social cognition.

fMRI in clinical and research applications 🔗

In clinical settings, fMRI is used for presurgical mapping – identifying which brain areas are critical for language or motor function before a tumor removal, so surgeons can avoid causing permanent deficits. It is also used to monitor how brain activity changes in response to treatment. For example, fMRI is used to track changes in neural activity in patients receiving antidepressant therapy, providing objective evidence of whether a treatment is altering brain function. In rehabilitation research, fMRI has helped map neuroplasticity – the brain’s capacity to reorganize itself after injury – by showing how undamaged regions gradually take over functions previously handled by damaged areas.

It is important to note that fMRI results are correlational rather than causal. The BOLD signal does not directly measure electrical activity in neurons; it infers neural activation from blood flow changes. This means that while fMRI can reliably identify which regions are active during a given task, it cannot by itself explain why those regions are involved or definitively establish a causal role. Researchers typically combine fMRI with other methods – behavioral experiments, lesion studies, or brain stimulation – to build stronger explanatory accounts.

Positron emission tomography (PET): imaging the brain’s chemistry 🔗

PET takes a different approach entirely. Rather than tracking blood flow or brain structure, PET measures the distribution of radioactive tracers injected into the bloodstream. These radiotracers are designed to bind to specific biological targets – glucose transporters, dopamine receptors, serotonin transporters, amyloid plaques – and as the radioactive atoms decay, they emit positrons that the scanner detects. The result is a map showing where and how intensely these molecular processes are occurring in the living brain.

The most commonly used PET tracer is fluorodeoxyglucose (FDG), a labeled form of glucose. Since active brain regions consume more glucose, FDG accumulation reflects regional metabolic activity. This makes FDG-PET especially useful for detecting areas of abnormal metabolism – hypometabolism in early Alzheimer’s disease, for example, appears in distinctive patterns in the temporal and parietal lobes long before structural changes become visible on MRI.

Neurotransmitter imaging with PET 🔗

Beyond metabolism, PET is uniquely capable of visualizing the brain’s neurochemical systems. A wide array of specialized radiotracers has been developed to bind to specific receptor subtypes. Researchers can use PET to measure dopamine D2/D3 receptor density, serotonin transporter availability, or the accumulation of amyloid and tau proteins – each offering a different window into the molecular machinery underlying behavior and disease.

In psychiatry, this capability has been transformative. PET imaging has enabled in-vivo assessment of neurotransmitter dynamics, receptor binding, and neuroinflammation across conditions including schizophrenia, major depression, and addiction. Research using PET has established, for example, that schizophrenia is associated with increased striatal dopamine synthesis and release, while depression is linked to reduced serotonergic transporter binding. These findings have directly informed the development of drug treatments that target these specific systems.

PET’s limitations include lower spatial resolution compared to MRI, exposure to a small amount of radiation from the radiotracer, and the significant cost and infrastructure required to produce short-lived radioisotopes. These factors limit its widespread clinical availability, though it remains indispensable in research and in specific diagnostic contexts such as pre-surgical evaluation for epilepsy and the differential diagnosis of dementia.

How these techniques are used together 🔗

In practice, no single imaging technique provides a complete picture. Neuropsychologists and clinicians routinely combine methods to answer different questions about the same patient or research participant. Structural MRI might confirm the presence of a brain lesion while fMRI reveals how surrounding tissue is compensating for it. CT might be used in an emergency when speed matters most, followed by MRI for detailed follow-up once the patient is stable.

Hybrid technologies are also advancing rapidly. Combined PET/MRI scanners allow simultaneous acquisition of structural, functional, and molecular data – providing an integrated view of brain anatomy, hemodynamics, and neurochemistry in a single session. This is particularly valuable in dementia research, where identifying both the structural atrophy and the specific pattern of amyloid or tau deposition can significantly improve diagnostic accuracy and treatment planning.

Researchers are also combining fMRI with PET to study neurotransmitter dynamics in real time, linking changes in receptor occupancy to the hemodynamic signals that fMRI detects. Simultaneous PET/fMRI acquisition offers an unprecedented opportunity to study how specific neurotransmitter systems drive dynamic changes in brain activity – a level of biological detail that neither method can achieve on its own.

Applications in understanding brain health and disease 🔗

Across all four modalities, in-vivo imaging has profoundly expanded what we know about the brain in health and disease. Some of the most clinically significant applications include:

Alzheimer’s disease and dementia: MRI tracks progressive cortical atrophy, while PET with amyloid tracers can detect the characteristic plaques of Alzheimer’s disease before cognitive symptoms fully emerge. This pre-symptomatic detection is critical for clinical trials of disease-modifying therapies.

Stroke: CT rapidly identifies hemorrhage in the acute phase; MRI’s diffusion-weighted imaging then precisely maps the ischemic core and the potentially salvageable tissue surrounding it, guiding time-sensitive treatment decisions.

Psychiatric disorders: fMRI and PET have revealed consistent patterns of altered brain activity in depression, schizophrenia, PTSD, and OCD – moving psychiatry toward a more neurobiologically grounded understanding of conditions that were once described purely in behavioral terms.

Brain tumors and epilepsy: fMRI maps eloquent cortex prior to surgery, reducing the risk of postoperative deficits. PET with FDG identifies hypometabolic seizure foci in patients being evaluated for epilepsy surgery, often complementing or reducing the need for more invasive electrophysiological monitoring.

Neuroplasticity and rehabilitation: By scanning patients at multiple time points, researchers can document how the brain reorganizes itself following stroke, traumatic brain injury, or intensive rehabilitation – providing direct evidence for the efficacy of specific interventions and informing individualized treatment programs.

Limitations and the road ahead 🔗

Despite their power, in-vivo imaging techniques have important limitations. Cost remains a significant barrier – fMRI and PET scanners are expensive to purchase and operate, and access is uneven across healthcare systems worldwide. The interpretation of imaging data requires specialist expertise, and results can be misused if overinterpreted or applied outside their validated contexts.

Technically, fMRI offers strong spatial resolution but relatively limited temporal resolution – it cannot capture neural events that unfold in milliseconds, as the BOLD signal lags several seconds behind the underlying electrical activity. This is why researchers often pair fMRI with electroencephalography (EEG), which records brain electrical signals with millisecond precision, to capture both where and when cognitive processes occur. PET, meanwhile, exposes participants to small amounts of radiation, limiting how frequently it can be used in longitudinal or pediatric research.

Looking ahead, the field is moving toward higher-field MRI scanners that offer even greater spatial detail, more targeted PET radiotracers that can probe previously inaccessible molecular targets, and AI-assisted image analysis that can extract clinically meaningful patterns from complex datasets far more efficiently than human reviewers. Portable and wearable neuroimaging devices – though still in early development – hold the potential to bring brain monitoring outside the scanner and into everyday environments.

In-vivo imaging has already moved neuropsychology from inference and approximation to direct observation. The brain, once a near-total black box in living patients, is now something we can watch, measure, and map with remarkable precision – and the tools continue to improve.

What do you think? As in-vivo imaging becomes increasingly capable of detecting psychiatric or neurological conditions before symptoms appear, how should clinicians and researchers navigate the ethical implications of early diagnosis – particularly when effective treatments may not yet exist? And given that fMRI results are correlational rather than causal, how much weight should neuroimaging evidence carry in clinical decision-making compared to behavioral and clinical assessments?

References

1. https://www.simplypsychology.org/neuroimaging.html
2. https://www.brainline.org/slideshow/brain-imaging-what-are-different-types
3. https://rotel.pressbooks.pub/biologicalpsychology/chapter/tools-of-cognitive-neuroscience-brain-imaging-pet-and-mri/
4. https://www.numberanalytics.com/blog/ultimate-guide-brain-imaging-techniques-neuropsychology
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7385290/
6. https://psychiatryonline.org/doi/10.1176/appi.neuropsych.16030044
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3806202/
8. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00792/full
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3379170/